Abstract: Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.

Abstract: A two-tiered classification system that can be integrated with the current algorithm used by pathologists for identification of the site of origin for ‘malignancy with unknown primary’ is presented. In use, morphology, immunohistochemical (IHC) studies, and microarray-based top tier gene expression classifiers first subclassify cytokeratin positive carcinomas into adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma and urothelial carcinoma. Subsequently, organ-specific IHC-markers, if available, are used in conjunction with microarray-based second tier gene expression classifiers to assign the primary site of origin to the sample. This new hybrid approach combines IHC with a hierarchy of quantitative gene expression based classifiers into an algorithmic method that can assist pathologists to further refine and support their decision making process.

Abstract: Methods for predicting NF-kappaB (NF-kB) activity in a tumor, and more particularly to methods for predicting survival and therapeutic outcome, and selecting therapy in subjects with tumors, e.g., adenocarcinomas, e.g., lung adenocarcinomas and melanomas.

Abstract: The subject invention concerns methods for the detection, diagnosis, and/or prognosis of cancer by analyzing centrosomal features. In one embodiment, a method includes receiving an image of one or more cells; selecting a region of interest in one cell; segmenting the region of interest to delineate at least one centrosomal; extracting one or more features from the segmented image; and analyzing the extracted features to diagnose cancer. In another embodiment, the progression of cancer can be predicted through analysis and classification of the extracted features. In one embodiment, the method can be performed by a quantitative cancer analysis system including a diagnosis module and/or a prognosis module. In one embodiment, the method can be performed using an image processing system.

Abstract: A method of treating or preventing an immune disorder, such as graft versus host disease, in a subject. The method includes the administering a SHIP1 inhibitor, such as 3?-aminocholestane, to a subject in need of treatment. Thus, SHIP1 inhibitors taught herein represent a novel class of small molecules that have the potential to enhance allogeneic transplantation, boost innate immunity and improve the treatment of hematologic malignancies.

Abstract: Systems and methods are provided including a system for managing patient data. The system includes a computing system including a processing unit and a storage. The processing unit executes one or more programs for managing patient data. Managing patient data includes enrolling patients in a centralized care network including presenting each patient with an electronic enrollment interface, assigning each patient a patient identifier, and receiving an electronic consent to collect data. Managing patient data further includes providing patient data to the centralized care network including patient data relating to disease progression, clinical trials and treatments rendered.

Abstract: Compounds, compositions, and methods for treating multidrug resistance are disclosed. Suitable compounds are 2-substituted heterocyclic compounds.